Blog

Current and future therapeutic demands of Ondansetron

MedAnalytics

MedAnalytics defines DEMAND by measuring the quantity of a generic that required for clinical management. The MARKET DEMAND is the sum of the individual generic demand for a given time period. It only speculate a market size within the therapeutic class and validates a plan of a product in business consideration based on current and potential market demand. In Q2, 2017 to Q1 2019, Ondansetron market demand decreased at -5.53% CAGR. While demand for others grew: Prochlorperazine Maleate at -8.25% CAGR, Palonosetron at -12.78% CAGR, Meclizine Hydrochloride + Pyridoxine Hydrochloride at -1.8% CAGR, Chlorpromazine Hydrochloride at -19.32% CAGR, Promethazine Hydrochloride at -10.02% CAGR, Metoclopramide Hydrochloride at -18.14% CAGR, Prochlorperazine Mesilate at -12.16% CAGR, Meclizine Hydrochloride at -26.42% CAGR, Hyoscine Hydro Bromide at 7.99% CAGR, Aprepitant at -13.11% CAGR, Promethazine Theoclate at -8.08% CAGR, Granisetron at -19.1% CAGR and Isopropamide + Trifluoperazine at -17.87% CAGR. Over the forecast period of 2020 - 2022, Ondansetron market demand is expected to continue at 1.93% CAGR. While demand for others are expected to grow: Prochlorperazine Maleate at -7.58% CAGR, Palonosetron at -0.29% CAGR, Meclizine Hydrochloride + Pyridoxine Hydrochloride at 3.72% CAGR, Chlorpromazine Hydrochloride at -14.91% CAGR, Promethazine Hydrochloride at -8.66% CAGR, Metoclopramide Hydrochloride at -16.22% CAGR, Prochlorperazine Mesilate at -4.26% CAGR, Meclizine Hydrochloride at -78.26% CAGR, Hyoscine Hydro Bromide at 5.62% CAGR, Aprepitant at -33.75% CAGR, Promethazine Theoclate at -10.92% CAGR, Granisetron at -14.04% CAGR and Isopropamide + Trifluoperazine at -13.95% CAGR.

You might be interested to our other reports  

Get Registered for more detail